Current HIV Research is a pivotal journal dedicated to the latest advancements in the field of HIV research, published by Bentham Science Publishers Ltd. With a commitment to disseminating high-quality research, this journal serves as a critical resource for researchers, healthcare professionals, and students interested in infectious diseases and virology. The journal has an ISSN of 1570-162X and an E-ISSN of 1873-4251, reflecting its commitment to contemporary digital scholarship. Given its publication history spanning from 2003 to 2024, the journal has continually provided insights and peer-reviewed articles that foster knowledge and innovation in HIV research. Although it currently holds a Q3 ranking in Infectious Diseases and a Q4 ranking in Virology, these rankings underscore its importance as an emerging platform for critical research dialogue. Despite not being an Open Access journal, 'Current HIV Research' ensures that cutting-edge studies reach relevant practitioners and contribute to ongoing discourse in the medical community. By fostering an informed approach to HIV and its implications, this journal is an invaluable asset to those committed to advancing their expertise in this crucial area of health science.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

AIDS AND BEHAVIOR, published by SPRINGER/PLENUM PUBLISHERS, is a leading scholarly journal dedicated to the interdisciplinary study of HIV/AIDS, focusing particularly on the behavioral aspects of the epidemic. With an impressive impact factor reflected in its Q1 rankings across key categories including Infectious Diseases, Public Health, and Social Psychology, this journal serves as a vital resource for researchers, clinicians, and public health professionals. It encompasses a wide scope of research, from the psychosocial factors influencing HIV transmission to innovative interventions that promote safe practices. Although it does not offer open access, the journal's rigorous peer-review process ensures the dissemination of high-quality, impactful research. Covering data from 1997 to 2024, AIDS AND BEHAVIOR is positioned at the forefront of advancements in the field, making it an essential addition to any academic library and a must-read for those involved in combating HIV/AIDS.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Welcome to the Cardiovascular Journal of Africa, an esteemed publication dedicated to advancing the fields of Cardiology and Cardiovascular Medicine. Established in 1994 and published by CLINICS CARDIVE PUBL PTY LTD, this journal serves as a vital platform for researchers, practitioners, and students interested in innovative cardiovascular research and clinical practice within the African context and beyond. With a Q3 ranking in both relevant categories as of 2023, this journal contributes significantly to the growing corpus of medical literature. Although access is non-open, the journal features a diverse array of peer-reviewed articles that explore groundbreaking findings and practical applications in cardiovascular health, fostering knowledge exchange among professionals. Situated in South Africa, the Cardiovascular Journal of Africa is not just a repository of academic research; it is a cornerstone in the fight against cardiovascular diseases, addressing the unique challenges faced by populations across the continent.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.